Prevention of secretagogue-induced ulcers in the rat.
An inhibitor of gastric secretion, Pfizer UK -9040, a derivative of the antihistamine triprolidine, was given orally 50 to 100 mg per kg 1 hr before and at various times during a 24-hr subcutanwous infusion of ulcerogenic secretagogues. The higher the dose and the more frequent the dosage, the lower was the incidence, severity, number, and perforations of duodenal ulcers. The mechanisms by which UK -9040 prevents these ulcers is probably inhibition of gastric secretion.
D000818:Animals; D002217:Carbachol; D004305:Dose-Response Relationship, Drug; D004381:Duodenal Ulcer / Q000139:chemically induced / Q000517:prevention & control*; D005750:Gastric Juice / Q000378:metabolism*; D006632:Histamine; D008297:Male; D010418:Pentagastrin; D010439:Peptic Ulcer Perforation / Q000517:prevention & control; D011725:Pyridines / Q000627:therapeutic use*; D051381:Rats; D013268:Stimulation, Chemical; D014311:Triprolidine / Q000031:analogs & derivatives / Q000627:therapeutic use*
D011725:Pyridines; D014311:Triprolidine; D006632:Histamine; D002217:Carbachol; D010418:Pentagastrin